NDAORALTABLETPriority Review
Approved
Jan 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
14
Data completeness
7/8 — Comprehensive
Priority Review
AYVAKIT (avapritinib) by Blueprint Medicines is tyrosine kinase inhibitors [moa]. Approved for kinase inhibitor [epc]. First approved in 2020.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AYVAKIT (avapritinib) is an oral tyrosine kinase inhibitor tablet developed by Blueprint Medicines and approved by the FDA on January 9, 2020. It is indicated for treating gastrointestinal stromal tumors (GIST) and other conditions driven by KIT and PDGFRA mutations. The drug works by selectively inhibiting these kinases, blocking the molecular drivers of disease progression. It represents a precision medicine approach to kinase-driven malignancies in the competitive TKI landscape.
$0.1BPart D
15.8 years to LOEMechanism of Action
Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (14)
Avapritinib Rollover Study
Started Nov 2024
60 enrolled
Mastocytosis, Systemic
Avapritinib With Decitabine in Patients With SM-AHN
Started Mar 2024
34 enrolled
Systemic Mastocytosis With an Associated Hematologic Neoplasm
Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
Started Aug 2022
61 enrolled
Gastrointestinal Stromal Tumors
A Drug-drug Interaction Study of Avapritinib and Midazolam
Started Aug 2022
10 enrolled
Gastrointestinal Stromal TumorsGISTNon-resectable Advanced Solid Tumors+1 more
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA
Started Jul 2022
74 enrolled
Gastrointestinal Stromal TumorsUnresectable Solid TumorRecurrent Metastatic Malignant Neoplasm
Worked on AYVAKIT at Blueprint Medicines? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.